Introduction
Materials and methods
Study design and methodology
Inclusion and exclusion criteria
Search strategy and study screening
Methodological quality assessment
Data collection
Statistical analysis
Results
Included studies
Author and publication year | LoE | MINORS score | N° of hips, initial cohort/final cohort | N° of hips lost to follow-up and/or died | Age | Gender female | Follow-up |
---|---|---|---|---|---|---|---|
N°/N° | N° (%) | y.o., Mean ± SD/(range)* | N° (%) | Years, mean ± SD/(range)* | |||
Morshed et al. 2005 [7] | IV | 6 | 13/13 | 0 (0%) | 52.6 (40–82.2) | 5 (38.5%) | 2 ± 1.1 |
Levine et al. 2009 [8] | IV | 8 | 23/23 | 0 (0%) | 61.7 (30–85) | 15 (60%) | 4.1 (2–7) |
Lim et al. 2011 [9] | III | 16 | 23/23 | 0 (0%) | 58.5 (33–79) | 12 (52.2%) | 5.3 (2–10.3) |
Fink et al. 2016 [13] | IV | 9 | 81/76 | 5 (6.2%) | 70.7 ± 9.8 | 37 (48.7%) | 4.3 (2–9.8) |
Petrie et al. 2017 [14] | IV | 8 | 102/102 | 0 (0%) | 67 (33–83) | 56 (54.9%) | 5.7 (0.1–14.4) |
Shi et al. 2019 [15] | III | 12 | 48/48 | 0 (0%) | 59.3 (30–78) | 19 (39.6%) | 6 (2.1–11.8) |
Hardt et al. 2021 [16] | III | 16 | 32/32 | 0 (0%) | 71.3 ± 10.5 | 21 (65.6%) | 5.5 (3.2–7.5) |
Lancaster et al. 2021 [17] | III | 12 | 16/16 | 0 (0%) | 63 ± 9 | 11 (68.8%) | 2 |
Whittaker et al. 2022 [18] | III | 16 | 49/49 | 0 (0%) | 62 (32–86) | 19 (38.8%) | 2.9 (0.1–12.1) |
Rate and time of union and reinfection rate of ETO
Author and publication year | N° of Hips | ETO union rate | ETO union time | ETO reinfection rate |
---|---|---|---|---|
N° | N° (%) | Weeks, N° | N° (%) | |
Morshed et al. 2005 [7] | 13 | 13 (100%) | 15.6 | 3 (32.1%) |
Levine et al. 2009 [8] | 23 | 22 (95.7%) | 11.5 | 3 (13%) |
Lim et al. 2011 [9] | 23 | 23 (100%) | 10.6 | 1 (4.3%) |
Fink et al. 2016 [13] | 76 | 75 (98.7%) | 12 | 5 (6.6%) |
Petrie et al. 2017 [14] | 102 | 89 (87.3%) | N/A | 3 (2.9%) |
Shi et al. 2019 [15] | 48 | 45 (93.8%) | 12 | 2 (4.2%) |
Hardt et al. 2021 [16] | 32 | 31 (96.9%) | N/A | 4 (12.5%) |
Lancaster et al. 2021 [17] | 16 | N/A | N/A | 3 (18.8%) |
Whittaker et al. 2022 [18] | 49 | 49 (100%) | N/A | 10 (20.4%) |
Overall | 382 | 347 (94.8%)* | 12** | 34 (8.9%) |
Postoperative complications
Author and publication year | No° of hips | Dislocation | Periprosthetic fracture | Aseptic loosening | Sciatic Nerve palsy | Heterotopic ossification | Stem subsidence > 5 mm | HHS pre/post |
---|---|---|---|---|---|---|---|---|
N° | N° (%) | N° (%) | N° (%) | N° (%) | N° (%) | N° (%) | N°/N°, mean | |
Morshed et al. 2005 [7] | 13 | 4 (30.8%) | 3 (6.1%) | 1 (7.7%) | 0 (0%) | 6 (46.2%) | 3 (23.1%) | 25/68 |
Levine et al. 2009 [8] | 23 | 2 (8.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | N/A* |
Lim et al. 2011 [9] | 23 | 1 (4.3%) | 2 (4.2%) | 0 (0%) | 1 (4.3%) | 0 (0%) | 1 (4.3%) | 36.1/81.1 |
Fink et al. 2016 [13] | 76 | 5 (6.6%) | 4 (3.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (6.6%) | 46.9/86.6 |
Petrie et al. 2017 [14] | 102 | 4 (3.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | n/a |
Shi et al. 2019 [15] | 48 | 4 (8.3%) | 2 (8.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 30.2/85.7 |
Hardt et al. 2021 [16] | 32 | 4 (12.5%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 0 (0%) | 4 (12.5%) | 37.9/65.9 |
Whittaker et al. 2022 [18] | 49 | 6 (12.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (4.1%) | N/A |
Overall | 366 | 30 (8.2%) | 11 (3%) | 2 (0.5%) | 1 (0.3%) | 6 (1.6%) | 15 (4.1%) | 38.5/71.7 |
PROMs
Analysis of comparative studies
Findings* | ETO PJI versus non-ETO PJI patients | ETO PJI versus non-PJI ETO patients | |||
---|---|---|---|---|---|
Hardt et al. 2021 [16] | Lancaster et al. 2021 [17] | Shi et al. 2019 [15] | Whittaker et al. 2022 [18] | Lim et al. 2011 [9] | |
Reinfection rate | = | = | ↑ | = | N/A |
ETO union rate | N/A | N/A | N/A | = | = |
Re-debridement | ↑ | N/A | ↑ | N/A | N/A |
Femoral stem subsidence | = | = | = | = | = |
Dislocation | = | = | = | = | = |
Periprosthetic fracture | = | = | = | = | = |
Postop HHS | = | N/A | = | N/A | = |
Follow-up | = | = | = | = | = |